Mark T. Reding

Professor and Director
Center for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, MN, USA

Presentation(s):

• OC 02.4 - Persistence of Ad26.COV2.S-associated VITT and specific detection of VITT antibodies

  Saturday, July 9, 2022
  1:45 PM – 2:00 PM

• LB 01.3 - Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

  Sunday, July 10, 2022
  3:15 PM – 3:30 PM

• PB1123 - Annualised Bleeding Rate and Joint Health: Second Interim Analysis of the Real-world HEM-POWR Study Evaluating the Effectiveness of Damoctocog Alfa Pegol in Patients With Haemophilia A

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1188 - Efficacy and safety of eptacog beta for resolution of spontaneous versus traumatic bleeding episodes in patients with hemophilia A or B with inhibitors

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• VPB1189 - ATHN 16: Safety of Coagulation Factor VIIa (recombinant)-jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia A or B with Inhibitors, with or without Prophylactic Treatment

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM